Literature DB >> 17283919

Analysis of yearly variations in drug expenditure for one patient using data warehouse in a hospital.

Yufeng Chen1, Yasushi Matsumura, Katsuhiko Nakagawa, Shanmei Ji, Hirohiko Nakano, Tadamasa Teratani, Qiyan Zhang, Takahiro Mineno, Hiroshi Takeda.   

Abstract

Medical expense has grown rapidly in Japan. It could be caused by the increase of the patient number and the increase of medical expense per patient. We studied the latter factor on drug expenditure from 1996 to 2002 using the prescription data stored in the data warehouse of one hospital. We found that the drug expenditure per patient had increased 1.32 times. The mean number of prescriptions per patient increased 1.23 times and the mean expenditure of one medicine increased 1.08 times. These results demonstrated that drug expenditure for one patient had gradually increased. This was caused by both the rise in the number of medicines taken by one patient and the rise in the prices of medicines. The data warehouse in the hospital was useful for the analysis of the trends in medical expenditure for one patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283919     DOI: 10.1007/s10916-006-9039-7

Source DB:  PubMed          Journal:  J Med Syst        ISSN: 0148-5598            Impact factor:   4.460


  10 in total

1.  Health spending, access, and outcomes: trends in industrialized countries.

Authors:  G F Anderson; J P Poullier
Journal:  Health Aff (Millwood)       Date:  1999 May-Jun       Impact factor: 6.301

2.  Explaining drug spending trends: does perception match reality?

Authors:  R W Dubois; A J Chawla; C A Neslusan; M W Smith; S Wade
Journal:  Health Aff (Millwood)       Date:  2000 Mar-Apr       Impact factor: 6.301

3.  Population aging: a comparison among industrialized countries.

Authors:  G F Anderson; P S Hussey
Journal:  Health Aff (Millwood)       Date:  2000 May-Jun       Impact factor: 6.301

4.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

Review 5.  Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Authors:  Naoki Ikegami; Michael Drummond; Shunichi Fukuhara; Shuzo Nishimura; George W Torrance; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  Healthcare reform in Europe.

Authors:  P Belien
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

7.  The cost of prescription medicines to patients.

Authors:  P R Noyce; C Huttin; V Atella; G Brenner; F M Haaijer-Ruskamp; M Hedvall; R Mechtler
Journal:  Health Policy       Date:  2000-06       Impact factor: 2.980

8.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

Review 9.  Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.

Authors:  L Ruilope
Journal:  J Hypertens Suppl       Date:  1997-12

10.  Projecting future drug expenditures--2003.

Authors:  Nilay D Shah; James M Hoffman; Lee C Vermeulen; Robert J Hunkler; Karrie M Hontz
Journal:  Am J Health Syst Pharm       Date:  2003-01-15       Impact factor: 2.637

  10 in total
  2 in total

1.  Bridging the gap: leveraging business intelligence tools in support of patient safety and financial effectiveness.

Authors:  Jeffrey M Ferranti; Matthew K Langman; David Tanaka; Jonathan McCall; Asif Ahmad
Journal:  J Am Med Inform Assoc       Date:  2010 Mar-Apr       Impact factor: 4.497

2.  Clinical use of an enterprise data warehouse.

Authors:  R Scott Evans; James F Lloyd; Lee A Pierce
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.